| Range: | 2.335-6.055 | Vol Avg: | 2170504 | Last Div: | 0 | Changes: | 0.04 |
| Beta: | 0.35 | Cap: | 0.82B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Dec 11 2020 | Empoloyees: | 586 | ||
| CUSIP: | 00288U106 | CIK: | 0001703057 | ISIN: | CA00288U1066 | Country: | CA |
| CEO: | Dr. Carl L.G. Hansen Ph.D. | Website: | https://www.abcellera.com | ||||
ABCL 2.75 Stock Price AbCellera Biologics Inc.
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Stock Details
Neutral 0.00
AbCellera to Present at Upcoming Investor Conferences in December and January
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming I...
businesswire.com·Thu Nov 21 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow